The metabolomic signature derived from patients with metastatic colorectal cancer predicts overall survival and provides insight into potential new biomarkers that can be used to predict disease progression and personalize treatment.
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Abstract
Earlier detection of patients with metastatic colorectal cancer (mCRC) might improve their treatment and survival outcomes. In this study, we used proton nuclear magnetic resonance ( 1 H-NMR) to profile the serum metabolome in mCRC patients and determine whether a disease signature may exist that is strong enough to predict overall survival (OS). In 153 mCRC patients and 139 healthy subjects (HS) from three Danish hospitals, we profiled two independent sets of serum samples in a prospective Phase II study. In the training set, 1 H-NMR metabolomic profiling could discriminate mCRC patients from HS with a cross-validated accuracy of 100%. In the validation set, 96.7% of subjects were correctly classified. Patients from the training set with maximally divergent OS were chosen to construct an OS predictor. After validation, patients predicted to have short OS 
Introduction
Pattern recognition technologies in the omics world have been used for the diagnosis and prognosis of several tumor types using a variety of experimental platforms (1-3).
Metabolomics is a post-genomic research field concerned with the study of metabolic profiles in biological samples such as isolated cells (4), tissues (5) or bodyfluids (6) (7) (8) (9) (10) . In recent years, metabolomic studies have provided a significant contribution to the detailed understanding of the biochemical network and pathways in oncology (11) , highlighting the potential of metabolomic analyses of blood samples for the detection of cancers, including epithelial ovarian (12) , leukemia (13) , oral (14) , breast (15, 16) , prostate (11) , liver (17) as well as colorectal cancer (CRC) (18) (19) (20) (21) (22) (23) (24) (25) . CRC is the second most common cause of cancer related deaths in Europe (26) and the third most common cause of cancer related deaths in the United States (27) . The impact of colorectal carcinogenesis on the metabolic profile of tissues and serum has been tested by mass spectrometry (MS) (18) (19) (20) (21) , nuclear magnetic resonance (NMR) (22, 23) or a combination of the two analytical tools (24) .
Most of the symptoms associated with CRC do not manifest themselves until late in the progression of the disease and many patients have metastases at the time of initial diagnosis (27) . The overall survival (OS) of a patient is reduced considerably when the disease is diagnosed at a stage where it has spread to distant sites. In the past decade the OS of patients with metastatic CRC (mCRC) has improved due to new combinations of chemotherapy, including 5-Fluorouracil (FU), irinotecan and oxaliplatin (28) (29) (30) (31) (Table 1 and Table S1 ), and of serum samples from 139 healthy subjects (HS) ( Table 1 ). The statistical model generated from 1 H-NMR profiles of serum samples of subjects from two of the three hospitals can robustly discriminate HS (n=96) from patients with mCRC (n=45) with 100% cross-validated accuracy. General applicability of the resultant classifier was successfully validated in an independent set of 43 HS and 108 patients with mCRC from the third hospital. The capability of the 1 H-NMR profiles to predict OS after start of treatment with cetuximab and irinotecan using pre-treatment serum samples was tested on a set of 20 subjects of the training set with maximally divergent OS. The classifier was validated on the independent set of 108 mCRC patients.
Furthermore, through multivariate analysis, a number of serum metabolites were identified whose levels were significantly different in patients with mCRC as compared to HS, as well as between patients with short and long OS. These metabolites can provide hints both to define new biomarkers and to better understand the biochemistry involved in mCRC. normal; 9) All should be exposed to oxaliplatin-based treatment; and 10) The signed informed consent as per requirements of the Scientific Ethical Commitees.
The patients were followed until death or July 7 th , 2010 (39 
Controls
Serum samples were collected from 96 Danish healthy blood donors and 43 healthy subjects (hospital staff) ( Table 1) .
Serum sample preparation
Blood was collected into standard blood collection tubes and allowed to clot at room temperature for 30-120 minutes before centrifugation (1500 g for 10 minutes at 4 o C).
Serum was aliquoted and stored at -80 o C in Greiner® cryogenic vials. This procedure is compatible with the Standard Operating Procedures (SOPs) for metabolomic-grade serum samples recently defined (40) .
NMR sample preparation
Frozen serum samples were thawed at room temperature and shaken before use. Table 1 and Table S1 .
Statistical Analysis
Multivariate data analyses were performed on processed data by combining established methods (6, 41) . Projection to Latent Structure (PLS) was applied on processed data for dimension reduction using the SIMPLS algorithm as implemented in the R library "plsgenomics"; the Support Vector Machines (SVM) method was used for data classification using the "libsvm" module of the R library "e1071". Canonical Correlation Analysis (CA) was performed using the standard R function "cancor".
To assess the prediction ability of the model, a 10-fold Cross-Validation (CV) was performed by generating splits with a ratio 1:9 for the data set, that is by removing 10% of samples prior to any step of the statistical analysis, including PLS component selection. violation for SVM) was carried out by means of 5-fold CV on the remaining 90%. The whole procedure was repeated 100 times. Data classification using SVM was performed by applying the classifier on PLS scores. Accuracy, sensitivity and specificity were calculated using standard definitions. To estimate the classification/feature selection performance of our predictors, the statistical significance of all observations was further assessed through permutation tests.
Score contribution weights were examined to assess which metabolites were most responsible for the observed discrimination between groups (42). The relative concentrations of each metabolite were calculated by integrating the signals in the spectra.
Statistical significance was assessed using the nonparametric Kruskal-Wallis test. A P < 0.05 was considered statistically significant. Group-wise comparisons of distributions of clinical and demographic data were performed with the Fisher's exact test for the categorical variables and Kruskal-Wallis test for the continuous variables.
Kaplan-Meier survival curves were created using the R library "survival". The Wald test was used to calculate the statistical significance (P) of the differences between survival curves. Prognostic factors for OS were analyzed using the Cox proportional hazard regression.
All calculations were made using R (41) scripts developed in-house.
Results
Fingerprinting of mCRC
A schematic diagram of the present strategy for constructing and validating a metabolic signature in patients with mCRC before 3 rd line treatment with cetuximab and irinotecan is shown in Figure 1A . Patients with mCRC and HS ( 
training set were averaged on a total of 1000 random subsamplings (100-times-repeated 10-fold CV). This procedure consists of two nested loops of CV (Fig. 1A) : an outer loop (10-fold CV) for the estimation of the prediction accuracy and an inner loop (5-fold CV) for the optimization of the parameters of the classifier training procedure. Classification performances on the validation set were calculated from the model built on the training set with a 10-fold parameter optimization procedure. Accuracy, sensitivity and specificity of the PLS-SVM classifier are given in Table 2 ; excellent classification accuracies were found both for the training (100.0%) and the validation sets (96.7%). On a descriptive level, CA on PLS score (PLS-CA) was used to ascertain whether the spectral patterns of serum of patients with mCRC carry unique features with respect to those of HS. The resulting plot is shown in Figure 1B : a very good discrimination is clearly apparent.
The different age distribution between the patients with mCRC and HS could be a possible source of inhomogeneity in the training set (P < 0.01). Therefore, the same statistical analysis described above was repeated on a subgroup aged between 45 and 65 years (P = 0.23), providing a classification accuracy of 100.0% in the training set and 92.1% in the validation set (Table 2 ). These results demonstrate that the difference in age distribution in the two groups does not affect significantly the classification accuracy values.
PLS-SVM CV analysis was also repeated on a dataset built with 96 HS and the 17 patients with mCRC and ECOG-PS 0, obtaining a classification accuracy of 100.0% on the training set and 86.4% on the validation set (Table 2) , which indicates that a clear metabolic signature of the disease exists even in the serum of patients with mCRC and ECOG-PS 0.
Prediction of survival
The strong metabolic signature of mCRC observed in the present study suggests that even within patients with mCRC there may be statistically significant differences in the Table 3 . Figure 1D shows the Kaplan-Meier plots of the survival data for the 108 patients with mCRC of the independent validation set, segregated according to the ; Table 4 ).
ECOG-PS also provides a meaningful prediction (HR = 1.57; 95% CI, 1.20 to 2.06, P = 1.13 x 10 -5 ; KRAS patients were found to be almost equally distributed between the long OS and short OS groups (Table 3) . When a multivariate analysis on NMR and ECOG-PS is performed, only NMR profiling remains meaningful (Table 4 ). The predictive power of NMR profiling with respect to that of classical serological markers (YKL-40, CRP, CEA) status was also tested (full analysis to be published elsewhere by Dr. Benny V. Jensen); NMR profiling remains an independent and meaningful predictor, together with CRP levels.
Metabolites contributing to the mCRC fingerprint
An analysis of the PLS loadings was performed to identify the metabolites contributing to the mCRC fingerprint using the entire sets of patients with mCRC and HS. The values of the relative serum concentrations of metabolites were estimated through the integration of the signals in the NMR spectra. By comparing the spectra of the serum samples of patients with mCRC with those of HS, it appears that the patients with mCRC are characterized by lower serum levels (P < 0.05) of alanine, citrate, creatine, glutamine, peptide NHs, lactate, leucine, pyruvate, tyrosine and valine, and higher serum levels (P < 0.05) of 3-hydroxybutyrate, acetate, formate, glycerol, lipid (-CH 2 -OCOR), N-acetyl signal of glycoproteins, phenylalanine and proline (Table S2 and Figure 2A ).
To identify the metabolites that contribute to discriminate patients with short and long OS, we selected from the entire group of patients with mCRC those with extreme OS values.
By setting OS thresholds of > 24 months and < 3 months, 18 and 17 patients were selected, respectively. Analysis of the PLS loadings shows that patients with short OS are characterized by lower serum levels (P < 0.05) of creatine, lipid (-C=C-CH 2 -C=C-), lipid (-CH=CH-) and valine, and higher serum levels (P < 0.05) of lipid (-CH 2 -OCOR) and Nacetyl signal of glycoproteins (Table S3 and Figure 2B CAN-11-1543 contrary, the ECOG-PS is based on criteria that reflect how a patient's disease is progressing and how the disease affects the daily living abilities of the patient; it is therefore intrinsically associated with a certain degree of subjectivity (43) . Author Manuscript Published OnlineFirst on November 11, 2011; DOI: 10.1158/0008-5472. CAN-11-1543 signals due to lipids and VLDL. Although information on nutritional status is not available, the N-acetyl signal of glycoproteins suggests that underweight and normal weight patients with mCRC may be characterized by a significantly higher immune response, highlighting a link between cachexia and inflammatory response.
The relative low serum levels of lactate and the non-statistically significant changes in glucose levels are different from the observations in previous studies of patients with CRC (20, 22) and in other types of cancer where, commonly, serum lactate levels are high (12, 53) . However, relatively high serum levels of glucose and low levels of lactate, alanine and gluconeogenic amino acids were observed in patients with oral cancer (14) . This pattern was attributed to an altered energy metabolism (14) . Gluconeogenesis in the present study of patients with mCRC may mask anaerobic dissimilation of glucose (48) . From the comparison between patients with mCRC and HS it also emerges that high serum levels of 3-hydroxybutyrate are present in the patients with mCRC. This molecule is formed during fatty acid oxidation and its high levels may suggest a liver response to an increased energy demand needed for an increased hepatic gluconeogenesis (14) . Depletion of polyunsaturated lipids observed in patients with mCRC also fits in this scheme.
In summary, we found that the serum of patients with mCRC before 3 rd line therapy with cetuximab and irinotecan shows a signature of altered energy metabolism, which may reflect an increased gluconeogenesis and an accumulation of 3-hydroxybutyrate. Our findings also suggest that the overall 
